Paxlovid Alternative Is Similarly Effective

Patients with mild to moderate COVID-19 who were treated for 5 days with VV116, an investigational oral antiviral drug that is active against SARS-CoV-2, recovered as quickly from infection as did those treated with nirmatrelvir-ritonavir (Paxlovid), according to the results of a randomized noninferiority trial published in the New England Journal of Medicine.

The median time for symptoms to resolve was 4 days for those treated with VV116 and 5 days for those treated with nirmatrelvir-ritonavir, based on the results from participants in Shanghai, China.

The time to sustained resolution of symptoms and to the first negative SARS-CoV-2 test result were also similar for the 384 participants treated with VV116 and the 387 treated with nirmatrelvir-ritonavir. Participants treated with VV116 also experienced fewer adverse effects.

Source: https://jamanetwork.com/journals/jama/fullarticle/2801504?guestAccessKey=60700954-a946-4f0f-ab05-1fb07ec11d35&utm_source=fbpage&utm_medium=social_jama&utm_term=8850829588&utm_campaign=article_alert&linkId=200612643